<DOC>
	<DOCNO>NCT01145768</DOCNO>
	<brief_summary>To investigate safety tolerability TC-5214 follow oral administration single multiple ascend dos compare placebo .</brief_summary>
	<brief_title>To Investigate Safety Tolerability TC-5214 Following Oral Administration Multiple Doses 8 Days</brief_title>
	<detailed_description />
	<criteria>Male nonpregnant , nonlactating female , suitable vein cannulation repeat venipuncture Contraceptive use first dose investigational product until12 week last dose Body mass index ( BMI ) 19 32 kg/m2 weigh least 50 kg History clinically significant medical , neurologic psychiatric disease disorder , opinion Investigator Sponsor , may either put volunteer risk participation study , influence result History gastrointestinal surgery ( except cholecystectomy appendectomy ) unintentional rapid weight loss Volunteers history suicide attempt past year and/or see Investigator significant history risk suicide homicide , consider risk suicide homicide study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>December 2010</verification_date>
	<keyword>Double-blind</keyword>
	<keyword>randomize</keyword>
	<keyword>placebo-controlled</keyword>
	<keyword>parallel-group study</keyword>
	<keyword>Safety</keyword>
	<keyword>pharmacokinetics</keyword>
</DOC>